Portfolio / Life sciences
EpiEndo Pharmaceuticals.
A non-antibiotic macrolide platform focused on epithelial dysfunction and chronic respiratory disease.
Investment since 2014
A respiratory medicine platform.
EpiEndo is developing a non-antibiotic macrolide platform that addresses epithelial dysfunction and other drivers of inflammation in chronic respiratory diseases.
Ísborg invested during the company’s second financing round in 2014. Ísborg’s published portfolio describes the programme as being in a First-in-Human clinical trial.
Ísborg ehf.
Start a conversation.
For enquiries about Ísborg and its portfolio, contact the company directly.